Peptide Stacks & Regimens Studio
Precision multi-peptide research cycles engineered with separate physical lyophilized vials. Features interactive diluent stoichiometry, live U-100 syringe graduation visualizers, synchronized 7-day administration schedules, and 1-click complete kit fulfillment.
Peptide Stacking & Multi-Product Compatibility Studio
Evaluate whether multiple separate products are safe, synergistic, or contraindicated to run together in your research protocol. Search our catalog, discover verified compatible stacking partners, and generate synchronized co-administration protocols.
🔍 Search Peptides to Stack:
Type any compound name, target receptor, or biological indication to see stack options.
Peptides that can be safely stacked with Epithalon (Epitalon)
Epithalon stimulates telomerase reverse transcriptase (TERT) to preserve chromosomal telomere length and circadian rhythm, while NAD+ directly fuels mitochondrial ATP synthesis and activates Sirtuin enzymes (SIRT1/SIRT3) for cellular DNA repair.
Angiogenesis, granulation tissue formation, nitric oxide synthesis
Systemic cell migration, microvascular remodeling, scar tissue prevention
Stimulates anterior pituitary GH transcription & physiological pulsatile release
Triggers amplified somatotrope vesicular release without raising prolactin or cortisol
Glucose-dependent insulinotropic polypeptide + glucagon-like peptide-1 appetite & insulin modulation
Central satiety signaling, delayed gastric emptying, insulin sensitization
Synergistic Multi-Pathway Amplification
The selected products exert complementary pharmacological actions across distinct receptor targets, producing therapeutic effects superior to either agent alone.
NAD+: 50–100 mg SubQ / IM (slow push upon waking)
Epithalon: 5–10 mg SubQ pre-bed (10 consecutive days)
Epithalon: Daily for 10-20 days. NAD+: 2-3x weekly ongoing.
10 to 20 days intense pulse on · Repeat 6 months later
Epithalon + NAD+
Epithalon stimulates telomerase reverse transcriptase (TERT) to preserve chromosomal telomere length and circadian rhythm, while NAD+ directly fuels mitochondrial ATP synthesis and activates Sirtuin enzymes (SIRT1/SIRT3) for cellular DNA repair.
NAD+: Morning SubQ or slow IM. Epithalon: Evening pre-bed SubQ for a 10–20 day cycle twice per year.
Inject NAD+ slowly over 60 seconds to prevent transient chest tightness or flushing.
Synchronized Stoichiometry, Syringe Calibrator & Kit Builder
Live stoichiometric recalculations, syringe tick marks, and 1-click kit fulfillment for all 2 active vials in this regimen.
Dual-Channel Reconstitution & Stoichiometry Station
Independent volumetric stoichiometry, fluid graduation, and U-100 syringe barrel calibration for each constituent physical vial.
Interactive Syringe Calibration & Reconstitution Stoichiometry— Epithalon (Epitalon)
Constituent Channel #1 of 2 (Epithalon (Epitalon))
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
| Escalation Stage & Phase | Target Dose | U-100 Mark (5mg / 1.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| Phase 1: Epigenetic Induction & Pineal Activation (Days 1–5) | 5.0 mg daily (5000 mcg) | 100.0 Units(1.00 mL) | 1x Daily | |
| Phase 2: Cellular Rejuvenation Block (Days 6–20) | 5.0 mg – 10.0 mg daily | 100.0 Units(1.00 mL) | 1x Daily | |
| Phase 3: Extended Washout & Maintenance (Month 2–6) | Observation Period | 0.0 Units(0.00 mL) | Zero dosing |
| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 2.50 mg (Micro Dose) | 0.50 mL | 50 Units 50.0 units (0.50 mL) on U-100 syringe |
| 5.00 mg (Standard Target) | 1.00 mL | 100 Units 100.0 units (1.00 mL) on U-100 syringe |
Introduce 2.0 mL diluent slowly down the glass wall. Epithalon dissolves spontaneously in seconds. Swirl gently horizontally for 30 seconds. Do not shake.
Never re-insert a needle into Vial B after drawing from Vial A. Doing so introduces cross-compound enzymes and permanently ruins lot purity.
Always use separate U-100 insulin syringes for each constituent compound. Ensure both syringes are labeled before administration.
Dispense constituent peptides into isolated in-vitro assay channels or separate analytical vessels to prevent unquantified cross-reactivity prior to scheduled observation.
Standard Operating Procedure (SOP): Multi-Peptide Stack Protocol
1. Pharmacodynamic Stacking Overview & Synergy Evaluation
The selected products exert complementary pharmacological actions across distinct receptor targets, producing therapeutic effects superior to either agent alone.
2. Multi-Vial Reconstitution Stoichiometry Station (2 Individual Vials)
| Vial # | Compound Name | Vial Mass | Diluent Vol | Concentration | Target Assay Dose | U-100 Syringe Draw |
|---|---|---|---|---|---|---|
| Vial #1 | Epithalon (Epitalon) | 10 mg | 2 mL | 5 mg/mL | 5.0 mg – 10.0 mg daily (in cyclical 10–20 day blocks) | 100.0 units (1.00 mL) |
| Vial #2 | NAD+ (Nicotinamide Adenine Dinucleotide) | 500 mg | 5 mL | 100 mg/mL | 50 mg – 100 mg (2–3x weekly) | 50.0 units (0.50 mL) |
3. Co-Administration Schedule & Timing Synchronization
NAD+: 50–100 mg SubQ / IM (slow push upon waking)
Epithalon: 5–10 mg SubQ pre-bed (10 consecutive days)
Weekly Rhythm: Epithalon: Daily for 10-20 days. NAD+: 2-3x weekly ongoing.
Cycle Length: 10 to 20 days intense pulse
Mandatory Washout: Repeat 6 months later
- Strict Syringe Separation: Maintain separate sterile U-100 syringes for each individual reconstituted vial. NEVER draw multiple peptide solutions into a single syringe.
- Precipitation Guardrail: Differing pH buffers (e.g. alkaline copper peptides vs acidic peptide solutions) will precipitate out of solution and aggregate if co-mingled in liquid phase.
- Vial Septum Access Rotation: Rotate cannula puncture positions across the rubber vial septum (avoid repeated punctures at identical coordinates to preserve septum integrity and prevent elastomeric coring).
- Refrigerated Storage: Store reconstituted vials at 2°C – 8°C (36°F – 46°F) protected from direct UV light.